Axogen pairs a $200 million BioCircuit acquisition with a share offering
Axogen ($AXGN) agreed to acquire BioCircuit Technologies for $200 million in cash, adding the NerveTape platform for sutureless peripheral-nerve repair. The buyer expects the transaction to support revenue growth and improve adjusted EBITDA margin and adjusted earnings per share in the first full fiscal year after completion. It also intends to maintain positive free cash flow. Alongside the acquisition, Axogen priced an offering of 4.91 million common shares at $42.50 each, generating approxima
0